Protection by apomorphine in two independent models of acute inhibition of oxidative metabolism in rodents

Clinical and Experimental Hypertension

Volumn 28, Issue 3-4, 2006, Pages 387-394

  Castri, Paola ^a   Busceti, Carla ^b   Battaglia, Giuseppe ^b   Girardi, Francesca ^a   Cavallari, Michele ^a   Orzi, Francesco ^a,d   Fornai, Francesco ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Apomorphine; Gerbil; Ischemia; Mice; MPTP; Neuroprotection; Oxidative metabolism

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; APOMORPHINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT;

AEROBIC METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN ISCHEMIA; CAROTID ARTERY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; GERBIL; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; ANIMAL; ARTICLE; C57BL MOUSE; CAROTID ARTERY OBSTRUCTION; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFECT; INTOXICATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; OXIDATIVE STRESS; TREATMENT OUTCOME;

ANIMALS; APOMORPHINE; BRAIN ISCHEMIA; CAROTID STENOSIS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGONISTS; GERBILLINAE; INFUSIONS, INTRAVENOUS; MICE; MICE, INBRED C57BL; MPTP POISONING; OXIDATIVE STRESS; TREATMENT OUTCOME;

EID: 33746427633     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960600549827     Document Type: Conference Paper

References (39)

1. Hunter AJ, Mackay KB, Rogers DC. To what extent have functional studies of ischaemia in animals been useful in the assessment of potential neuroprotective agents? Trends Pharmacol Sci 1998; 19:59-66.
2. De Keyser J Sulter G, Luiten PG. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? Trends Neurosci 1999; 22:535-40.
3. Wenning GK, Bosch S, Luginger E, Wagner M, Poewe W. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease. Adv Neurol 1999; 80:545-548.
4. Suzuki R, Yamaguchi T, Kirino T, Orzi F, Klatzo I. The effects of 5-minute ischemia in Mongolian gerbils: I. Blood-brain barrier, cerebral blood flow, and local cerebral glucose utilization changes. Acta Neuropathol (Berl) 1983; 60:207-216.
5. Kondo T, Ito T, Sugita Y. Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum. Ann NY Acad Sci 1994; 738:222-229.
6. Liu XH, Kato H, Chen T, Kato K, Itoyama Y. Bromocriptine protects against delayed neuronal death of hippocampal neurons following cerebral ischemia in the gerbil. J Neurol Sci 1995; 129:9-14.
7. Muralikrishnan D, Mohanakumar KP. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.. FASEB J 1998; 12:905-912.
8. Ogawa N, Tanaka K, Asanuma M, Kawai M, Masumizu T, Kohno M, Mori A. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res 1994; 657:207-213.
9. Felten DL, Felten SY, Fuller RW, Romano TD, Smalstig EB, Wong DT, Clemens JA. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats. Neurobiol Aging 1992; 13:339-51.
10. O'Neill MJ, Hicks CA, Ward MA, Cardwell GP, Reymann JM, Allain H, Bentue-Ferrer D. Dopamine D2 receptor agonists protect against ischaemia-induced hippocampal neurodegeneration in global cerebral ischaemia. Eur J Pharmacol 1998; 352:37-46.
11. Opacka-Juffry J, Wilson AW, Blunt SB. Effects of pergolide treatment on in vivo hydroxyl free radical formation during infusion of 6-hydroxydopamine in rat striatum. Brain Res 1998; 810:27-33.
12. Coldwell MC, Boyfield I, Brown T, Hagan JJ, Middlemiss DN. Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 1999; 127:1696-1702.
13. Iida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, Ogawa N. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 1999; 838:51-59.
14. Carvey PM, Pieri S, Ling ZD. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm 1997; 104:209-228.
15. Hall ED, Andrus PK, Oostveen JA, Althaus JS, VonVoigtlander PF. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res 1996; 742:80-88.
16. Ling ZD, Robie HC, Tong CW, Carvey PM. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures. J Pharmacol Exp Ther 1999; 289:202-210.
17. Caldwell MA, Reymann JM, Allain H, Leonard BE, Bentue-Ferrer D. Lisuride prevents learning and memory impairment and attenuates the increase in extracellular dopamine induced by transient global cerebral ischemia in rats. Brain Res 1997; 771:305-318.
18. Delbarre B, Delbarre G, Rochat C, Calinon F. Effect of piribedil, a D-2 dopaminergic agonist, on dopamine, amino acids, and free radicals in gerbil brain after cerebral ischemia. Mol Chem Neuropathol 1995; 26:43-52.
19. Gassen M, Gross A, Youdim MB. Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine. Mov Disord 1998; 13:661-667.
20. Grunblatt E, Mandel S, Gassen M, Youdim MB. Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity. J Neural Transm Suppl 1999; 55:57-70.
21. Grunblatt E, Mandel S, Maor G, Youdim MB. Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss. J Neurochem 2001; 77:146-156.
22. Carvey PM, McGuire SO, Ling ZD. Neuroprotective effects of D3 dopamine receptor agonists 2001; 7:213-223.
23. Grunblatt E, Mandel S, Berkuzki T, Youdim MB. Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov Disord 1999; 14:612-618.
24. Caldwell MA, Reymann JM, Bentue-Ferrer D, Allain H, Leonard BE. The dopamine agonists lisuride and piribedil protect against behavioural and histological changes following 4-vessel occlusion in the rat. Neuropsychobiology 1996; 34:117-124.
25. Agid Y, Javoy F, Glowinski J. Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. Nat New Biol 1973; 245:150-151.
26. Melamed E, Hefti F, Wurtman RJ. Compensatory mechanisms in the nigrostriatal dopaminergic system in Parkinson's disease: studies in an animal model. Isr J Med Sci 1982; 18(1):159-163.
27. Globus MY, Busto R, Dietrich WD, Martinez E, Valdes I, Ginsberg MD. Effect of ischemia on the in vivo release of striatal dopamine, glutamate, and gamma-aminobutyric acid studied by intracerebral microdialysis. J Neurochem 1988; 51:1455-1464.
28. Lin MT, Kao TY, Chio CC, Jin YT. Dopamine depletion protects striatal neurons from heatstroke-induced ischemia and cell death in rats. Am J Physiol 1995; 269:H487-H490.
29. Sonsalla PK, Gibb JW, Hanson GR. Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems. J Pharmacol Exp Ther 1986; 238:932-937.
30. Battaglia G, Gesi M, Lenzi P, Busceti CL, Soldani P, Orzi F, et al. Morphological and biochemical evidence that apomorphine rescues striatal dopamine terminals and prevents methamphetamine toxicity. Ann NY Acad Sci 2002; 965:254-266.
31. Fornai F, Battaglia G, Gesi M, Orzi F, Nicoletti F, Ruggieri S. Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage. Brain Res 2001; 898:27-35.
32. Olanow CW, Jenner P, Brooks D. Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol 1998; 44:S167-174.
33. Ling ZD, Tong CW, Carvey PM. Partial purification of a pramipexole-induced trophic activity directed at dopamine neurons in ventral mesencephalic cultures. Brain Res 1998; 79:137-145.
34. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna JM. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 2001; 65:135-172.
35. Kohutnicka M, Lewandowska E, Kurkowska-Jastrzebska I, Czlonkowski A, Czlonkowska A. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 1998; 39:167-180.
36. Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A. MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson's disease. Acta Neurobiol Exp (Wars) 1999; 59:1-8.
37. Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine intoxication in mouse. Exp Neurol 1999; 156:50-61.
38. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999; 46:598-605.
39. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988; 38:1285-1291.